Key Points
- Insider sale: Terilyn Monroe sold 8,571 Guardant Health shares on Jan. 21 at an average price of $114.09 for about $977,865, trimming her stake by 28.99% to 20,990 shares (SEC filing disclosed).
- Company and market view: GH stock rose ~1.3% after the company reported an EPS beat (‑$0.39 vs. est. ‑$0.48) and 38.5% revenue growth, while analysts have lifted targets and the consensus rating is a "Moderate Buy" with a $102.81 price target.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Terilyn Monroe sold 8,571 shares of the company's stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total transaction of $977,865.39. Following the completion of the sale, the insider directly owned 20,990 shares in the company, valued at approximately $2,394,749.10. The trade was a 28.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Guardant Health Stock Up 1.3%
Shares of GH opened at $117.28 on Friday. The company has a 50-day moving average price of $104.83 and a two-hundred day moving average price of $77.00. The stock has a market cap of $14.78 billion, a price-to-earnings ratio of -36.54 and a beta of 1.58. Guardant Health, Inc. has a 12 month low of $34.88 and a 12 month high of $120.74.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. The company's quarterly revenue was up 38.5% on a year-over-year basis. During the same period last year, the firm earned ($0.88) earnings per share. Equities research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Guardant Health from $105.00 to $130.00 and gave the company an "overweight" rating in a research note on Monday, December 1st. Barclays lifted their price target on shares of Guardant Health from $85.00 to $120.00 and gave the company an "overweight" rating in a report on Monday, December 15th. Stifel Nicolaus upped their price objective on shares of Guardant Health from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Friday, January 9th. Mizuho set a $135.00 price objective on shares of Guardant Health in a report on Friday, January 9th. Finally, Evercore ISI set a $105.00 target price on Guardant Health and gave the stock an "in-line" rating in a report on Monday, January 5th. Twenty-one investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $102.81.
Check Out Our Latest Stock Report on GH
Hedge Funds Weigh In On Guardant Health
A number of large investors have recently modified their holdings of GH. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health during the fourth quarter valued at approximately $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the 4th quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Guardant Health during the 4th quarter worth $31,000. IFP Advisors Inc boosted its position in Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company's stock valued at $33,000 after buying an additional 334 shares during the last quarter. Finally, Signaturefd LLC increased its stake in shares of Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company's stock valued at $33,000 after buying an additional 213 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
